Vemurafenib

Izvor: Wikipedija
Prijeđi na navigaciju Prijeđi na pretragu
Vemurafenib
Klinički podaci
AHFS/Drugs.com Monografija
Identifikatori
CAS broj 918504-65-1
ATC kod L01XE15
PubChem[1][2] 42611257
DrugBank DB08881
ChemSpider[3] 24747352
ChEBI CHEBI:63637DaY
ChEMBL[4] CHEMBL1229517DaY
Hemijski podaci
Formula C23H18ClF2N3O3S
Mol. masa 489,922
SMILES eMolekuli&PubHem
Farmakokinetičkipodaci
Poluvreme eliminacije 57 h
Farmakoinformacioni podaci
Trudnoća ?
Pravni status
Način primene Oralno

Vemurafenibjeorgansko jedinjenje,koje sadrži 23atomaugljenikai imamolekulsku masuod 489,922Da.[5][6][7]

Osobine

[uredi|uredi kod]
Osobina Vrednost
Broj akceptora vodonika 4
Broj donora vodonika 2
Broj rotacionih veza 7
Particioni koeficijent[8](ALogP) 5,0
Rastvorljivost[9](logS,log(mol/L)) -7,5
Polarna površina[10](PSA,Å2) 100,3

Reference

[uredi|uredi kod]
  1. Li Q, Cheng T, Wang Y, Bryant SH (2010).„PubChem as a public resource for drug discovery.”.Drug Discov Today15(23-24): 1052-7.DOI:10.1016/j.drudis.2010.10.003.PMID20970519.edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”.Annual Reports in Computational Chemistry4:217-241.DOI:10.1016/S1574-1400(08)00012-1.
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010).„Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”.J Cheminform2(1): 3.DOI:10.1186/1758-2946-2-3.PMID20331846.edit
  4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”.Nucleic Acids Res40(Database issue): D1100-7.DOI:10.1093/nar/gkr777.PMID21948594.edit
  5. Jordan EJ, Kelly CM: Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2012 Dec;13(17):2533-43. doi: 10.1517/14656566.2012.737780. Epub 2012 Oct 24.PMID23094782
  6. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011).„DrugBank 3.0: a comprehensive resource for omics research on drugs”.Nucleic Acids Res.39(Database issue): D1035-41.DOI:10.1093/nar/gkq1126.PMC3013709.PMID21059682.edit
  7. David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008).„DrugBank: a knowledgebase for drugs, drug actions and drug targets”.Nucleic Acids Res36(Database issue): D901-6.DOI:10.1093/nar/gkm958.PMC2238889.PMID18048412.edit
  8. Ghose, A.K., Viswanadhan V.N., and Wendoloski, J.J. (1998).„Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”.J. Phys. Chem. A102:3762-3772.DOI:10.1021/jp980230o.
  9. Tetko IV, Tanchuk VY, Kasheva TN, Villa AE. (2001).„Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”.Chem Inf. Comput. Sci.41:1488-1493.DOI:10.1021/ci000392t.PMID11749573.edit
  10. Ertl P., Rohde B., Selzer P. (2000).„Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”.J. Med. Chem.43:3714-3717.DOI:10.1021/jm000942e.PMID11020286.edit

Literatura

[uredi|uredi kod]

Spoljašnje veze

[uredi|uredi kod]